Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Add To Watchlist

Recent & Breaking News (NYSE:TAK)

Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Business Wire February 3, 2021

Takeda Completes Sale of TachoSil® to Corza Health

Business Wire February 1, 2021

Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

Business Wire January 29, 2021

Takeda Applies to Cease being a Reporting Issuer in Canada

Canada NewsWire January 28, 2021

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

Business Wire January 28, 2021

Takeda Achieved Carbon Neutrality in 2020

Business Wire January 27, 2021

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index

Business Wire January 26, 2021

Takeda Named Global Top Employer for Fourth Consecutive Year

Business Wire January 24, 2021

Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 11, 2021

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 11, 2021

Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

Business Wire January 5, 2021

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

Business Wire December 21, 2020

U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

Business Wire December 18, 2020

Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]

PR Newswire December 16, 2020

U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Business Wire December 15, 2020

Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

Business Wire December 8, 2020

Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

Business Wire December 8, 2020

Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders

Business Wire December 7, 2020

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

GlobeNewswire December 4, 2020

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

Business Wire December 4, 2020